The R4 Race Committee recently met with representatives of LLS to better understand the research and work being done in the area of GVHD. They have provided us with information about the work LLS is funding in the GVHD area and I believe that you will find it to be impressive.
Linked are two documents: the SCT Portfolio and (SCOR) Specialized Center of Research, recipient Dr. Irwin Bernstein. The SCT portfolio funding is $7mil and Dr. Bernstein’s work is funded at $6mil for a total of $13mil just in the area of GVHD.
Active Research Portfolio Projects:
- The SCT Portfolio includes cutting-edge investigations underway at eight prestigious research institutions around the world. Highlights include new transplant regimens using stem cells from bone marrow, peripheral and umbilical cord blood, new strategies to predict, prevent and/or ameliorate infections, GVHD and cognitive deficits that can occur after transplantation, as well new approaches to further reducing post-transplant relapses.
- Dr. Bernstein’s team is working to develop less toxic and more effective immune-based therapies for leukemia and lymphoma patients. These new therapies are designed to harness the full curative power of blood stem cell transplants, while avoiding life-threatening complications such as graft-versus-host disease (GVHD) and serious infections.